Introduction GLP1 medications do not appear to cause suicidal thoughts or severe psychiatric harm based on the largest regulatory reviews to date
These common interactions involve two salt bridges with E 6.53b and E/D 7.42b (via the positively charged N-terminal nitrogen atom of Y1 P ), stacking interactions with W39 GLP-1R /W39 GIPR /W36 GCGR (via F22 P ), Y 1.43b (via F6 P ) and W 5.36b (via Y1 P ), multiple hydrogen bonds with L32 GLP-1R /A32 GIPR /M29 GCGR (via D15 P ), Y 1.43b (via Q3 P ), Y 1.47b (via Q3 P ), T/E 45.52b (via S11 P ) and N300 GLP-1R /N290 GIPR /N298 GCGR (via S8 P ), along with extensive hydrophobic contacts with L/Y 1.36b (via Y10 P and MeL13 P ), I/V 3.40b (via Y1 P ), W 5.36b (via G4 P ), L 7.39b and I/L 7.43b (via Aib2 P )
See peptide therapy and wellness lounge for our metabolic and wellness offerings
[52] The first six amino acids of GLP-1 are missing
Open communication with your healthcare team ensures safe, effective use of GLP-1 medications while minimizing the risk of hypotension and other adverse effects
The Mechanistic Overlap Both drugs share the GIP and GLP-1 receptor targets
